{"id":948,"date":"2021-04-29T05:32:08","date_gmt":"2021-04-29T05:32:08","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=948"},"modified":"2021-04-29T05:32:08","modified_gmt":"2021-04-29T05:32:08","slug":"02-apr-2021-favipiravir-safe-effective-alternative-for-hydroxychloroquine-in-mild-or-moderate-covid-19-infected-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/02-apr-2021-favipiravir-safe-effective-alternative-for-hydroxychloroquine-in-mild-or-moderate-covid-19-infected-patients\/","title":{"rendered":"(02 Apr 2021) Favipiravir- safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial<\/p>\n<p>https:\/\/doi.org\/10.1038\/s41598-021-85227-0<\/p>\n<p class=\"\">NCT04349241- t was randomized-controlled open-label interventional phase 3 clinical trial. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2-day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2-10) and oral oseltamivir 75 mg\/12 h\/day for 10 days.&nbsp; The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at\/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial https:\/\/doi.org\/10.1038\/s41598-021-85227-0 NCT04349241- t was randomized-controlled open-label interventional phase 3 clinical trial. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/02-apr-2021-favipiravir-safe-effective-alternative-for-hydroxychloroquine-in-mild-or-moderate-covid-19-infected-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(02 Apr 2021) Favipiravir- safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/948"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=948"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/948\/revisions"}],"predecessor-version":[{"id":949,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/948\/revisions\/949"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}